[go: up one dir, main page]

PT1680403T - Análogos de deoxinojirimicina e seus usos como inibidores de glucosilceramidase - Google Patents

Análogos de deoxinojirimicina e seus usos como inibidores de glucosilceramidase

Info

Publication number
PT1680403T
PT1680403T PT47936851T PT04793685T PT1680403T PT 1680403 T PT1680403 T PT 1680403T PT 47936851 T PT47936851 T PT 47936851T PT 04793685 T PT04793685 T PT 04793685T PT 1680403 T PT1680403 T PT 1680403T
Authority
PT
Portugal
Prior art keywords
glucosylceramidase
inhibitors
deoxynojirimycin analogues
deoxynojirimycin
analogues
Prior art date
Application number
PT47936851T
Other languages
English (en)
Inventor
Maria Franciscus Gerardus Aerts Johannes
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PT1680403T publication Critical patent/PT1680403T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT47936851T 2003-10-29 2004-10-29 Análogos de deoxinojirimicina e seus usos como inibidores de glucosilceramidase PT1680403T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078395A EP1528056A1 (en) 2003-10-29 2003-10-29 Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors

Publications (1)

Publication Number Publication Date
PT1680403T true PT1680403T (pt) 2016-09-07

Family

ID=34400526

Family Applications (1)

Application Number Title Priority Date Filing Date
PT47936851T PT1680403T (pt) 2003-10-29 2004-10-29 Análogos de deoxinojirimicina e seus usos como inibidores de glucosilceramidase

Country Status (14)

Country Link
US (1) US7528153B2 (pt)
EP (2) EP1528056A1 (pt)
JP (2) JP5016925B2 (pt)
AU (1) AU2004284012B2 (pt)
CA (1) CA2551060C (pt)
CY (1) CY1118191T1 (pt)
DK (1) DK1680403T3 (pt)
ES (1) ES2594356T3 (pt)
HU (1) HUE029637T2 (pt)
IL (1) IL175260A0 (pt)
PL (1) PL1680403T3 (pt)
PT (1) PT1680403T (pt)
SI (1) SI1680403T1 (pt)
WO (1) WO2005040118A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283631A1 (en) * 2003-10-29 2005-05-06 Genzyme Corporation Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
US20060025449A1 (en) * 2004-03-25 2006-02-02 United Therapeutics Use of N-substituted imino sugars for appetite suppression
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
FR2887549B1 (fr) * 2005-06-23 2009-07-10 Centre Nat Rech Scient Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
FR2894482A1 (fr) * 2005-12-14 2007-06-15 Galderma Sa Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema
US8410081B2 (en) * 2006-04-24 2013-04-02 Academisch Medisch Centrum Treatment of cystic fibrosis
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
EP2594563B1 (en) 2007-05-31 2018-07-18 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009045503A1 (en) 2007-10-05 2009-04-09 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
CA2738768C (en) 2008-10-03 2017-10-31 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
PT2398500T (pt) * 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
US20100248365A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
CA2783405A1 (en) * 2009-12-07 2011-06-16 The Chancellor, Masters And Scholars Of The University Of Oxford N-substituted deoxynojirimycin compounds for use in inhibiting osteoclastogenesis and/or osteoclast activation
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
CA2799420C (en) 2010-05-14 2018-10-02 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
ES2371398B1 (es) * 2010-06-04 2013-05-20 Bioglane, S.L.N.E. Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales.
EP2533051A1 (en) 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
EP2885637B1 (en) * 2012-08-15 2016-11-30 The Procter & Gamble Company Use of human ex vivo skin model in a method of identifying modulators of skin inflammation
CA2906675A1 (en) 2013-03-15 2014-09-18 Unither Virology, Llc Antibacterial compounds
EP2991488A4 (en) * 2013-05-02 2016-12-21 The Chancellor Masters And Scholars Of The Univ Of Oxford GLYCOLIPID INHIBITION BY IMINO SUGAR
CN106456664A (zh) * 2013-05-02 2017-02-22 牛津大学之校长及学者 脂质组学生物标志物
RU2016105108A (ru) 2013-07-25 2017-08-30 Дана-Фарбер Кэнсер Инститьют, Инк. Ингибиторы факторов транскрипции и их применение
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3110424A1 (en) 2014-02-28 2017-01-04 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
EP3122726B1 (en) 2014-03-27 2018-08-29 Academisch Medisch Centrum N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
KR20170032473A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디아제판 유도체 및 그의 용도
MX2017001757A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180049058A (ko) 2015-09-11 2018-05-10 다나-파버 캔서 인스티튜트 인크. 시아노 티에노트리아졸로디아제핀 및 그의 용도
MX2018003030A (es) 2015-09-11 2018-04-11 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas.
JP7385356B2 (ja) 2015-11-25 2023-11-22 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド 二価ブロモドメインインヒビターおよびそれらの使用
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
US20220257604A1 (en) * 2019-03-08 2022-08-18 University Of Virginia Patent Foundation Compositions and methods for modulating viral infections by regulating glucosylceramides
US12528773B2 (en) * 2020-05-07 2026-01-20 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
WO2022227287A1 (zh) * 2021-04-25 2022-11-03 中南大学 Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用
CN118459393B (zh) * 2024-04-29 2025-11-28 中国科学院成都生物研究所 一类具有α-葡萄糖苷酶抑制活性的D-木糖衍生物及制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2504000B2 (ja) 1986-09-02 1996-06-05 日本新薬株式会社 グルコシルモラノリン誘導体
EP0912179B1 (en) * 1996-07-15 2006-04-12 MacroZyme DNM B.V. Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
BR9902585A (pt) 1999-02-11 2000-09-26 Claudio Cerqueira Lopes Um novo processo de sìntese de aza-açúcares com atividade biológica
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2004007454A1 (en) * 2002-07-17 2004-01-22 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
JP4575156B2 (ja) * 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
GB0229476D0 (en) 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
AU2004283631A1 (en) * 2003-10-29 2005-05-06 Genzyme Corporation Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2005063706A1 (en) 2003-12-23 2005-07-14 Macrozyme Dnm B.V. Synthesis of nojirimycins
WO2006125141A2 (en) 2005-05-17 2006-11-23 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin derivatives

Also Published As

Publication number Publication date
PL1680403T3 (pl) 2017-08-31
IL175260A0 (en) 2006-09-05
JP5730808B2 (ja) 2015-06-10
CA2551060C (en) 2012-08-28
US7528153B2 (en) 2009-05-05
CY1118191T1 (el) 2017-06-28
JP2012180353A (ja) 2012-09-20
EP1528056A1 (en) 2005-05-04
US20070066581A1 (en) 2007-03-22
ES2594356T3 (es) 2016-12-19
AU2004284012B2 (en) 2010-06-17
CA2551060A1 (en) 2005-05-06
SI1680403T1 (sl) 2017-01-31
HUE029637T2 (en) 2017-03-28
DK1680403T3 (en) 2016-09-26
JP5016925B2 (ja) 2012-09-05
AU2004284012A1 (en) 2005-05-06
EP1680403B1 (en) 2016-06-29
WO2005040118A1 (en) 2005-05-06
JP2007509926A (ja) 2007-04-19
EP1680403A1 (en) 2006-07-19

Similar Documents

Publication Publication Date Title
IL175260A0 (en) Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
PL372814A1 (en) Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
AP2089A (en) Compositions and methods for combination antiviraltherapy
EP1633718A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-S
EG25482A (en) Inhibitors
GB0411940D0 (en) Methods and compositions
IL187620A0 (en) 17??-hsd1 and sts inhibitors
SI1592686T1 (sl) Inhibitorji giraze in njihova uporaba
AU2003299034A8 (en) Transdermal compositions
AU2003256805A8 (en) Compounds compositions and methods
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003275268A8 (en) Hemostatic compositions and methods
EP1532133A4 (en) NF-: B INHIBITORS
EP1684771A4 (en) COMPOSITION AND METHOD
ZA200502843B (en) Methods and compositions for providing glutamine
AU2003299901A8 (en) Thrombin inhibitors
EP1765373A4 (en) OZONIZED PHARMACEUTICAL COMPOSITION AND METHOD THEREOF
AU2003268078A8 (en) Levothyroxine compositions and methods
AU2003222258A8 (en) Inhibitors for use in hemostasis
AU2003245524A8 (en) Cryosurgery compositions and methods
AU2003298035A8 (en) Compositions and methods for inhibiting malaria protease falcipain-2
AU2003238948A8 (en) Caspase-1 inhibitors and methods for their use
GB0330062D0 (en) Compositions and methods
IL165935A (en) Vasopeptidase inhibitors